Anixa Biosciences, Inc. (ANIX) Fair Value 2026

ANIX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.7 /10

32 fundamental signals · 7 models active

Value Trap Risk

SAFE (6/100)

Quick Summary — As of 2026-07-13, Anixa Biosciences, Inc. (ANIX) trades at $3.06, approximately 262% above CirclFi’s Bayesian DCF fair value of $0.84. QOC: 4.7/10. Value Trap Risk: 6/100 (SAFE). 7/13 models active.

Key Facts

Ticker
ANIX
Price
$3.06
Quality Score
4.7/10
Value Trap Risk
6/100
Models Active
7/13
Last Updated
Strength: First Chicago suggests +46.7% upside with 11% confidence
Risk: Below-average Quality Score of 4.7/10 signals weak fundamentals

Valuation Matrix

7 Intrinsic Value Models vs. Current Price ($3.06)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.84 -72.4%
CUCE Ensemble
Low Conviction
 $1.87 -39.0%
First Chicago
Low Conviction
 $4.49 +46.7%

Unlock the Full Matrix

Access 4 additional models including ML-RIV, Dynamic NAV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is Anixa Biosciences, Inc. (ANIX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Anixa Biosciences, Inc.'s intrinsic value is estimated at a composite fair value of $2.05. Trading at $3.06, the stock is approaching fair value or slight overvaluation (implied return of -32.9%), as 4 of 7 models suggest limited further upside. Notably, First Chicago sees the most upside at +46.7% (fair value: $4.49), while ML-RIV is the most conservative at -98.7% ($0.04). The spread between these extremes — +145.4% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About ANIX?

7 of 13 models are currently active for ANIX. Of these, 2 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates ANIX's intrinsic value at $0.84, implying -72.4% downside from the current price. See which stocks rank higher →

How Does ANIX Rank in Biotechnology?

Among 62 Biotechnology stocks, ANIX ranks #36 by Quality of Company score. CirclFi's QOC score of 4.7/10 evaluates 32 fundamental signals. A score of 4.7 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Anixa Biosciences, Inc.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including partnership and licensing deals — shape both the opportunity set and risk profile.

Is ANIX a Value Trap?

CirclFi's Value Trap algorithm assigns ANIX a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for Anixa Biosciences, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Anixa Biosciences, Inc. earns a quality score of 4.7/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +145.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ANIX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ANIX's 7 active models, average confidence is 16%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Anixa Biosciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

8 related Biotechnology stocks with 13-model coverage

ADMAADMA Biologics IncQOC 10.0ACADACADIA Pharmaceuticals Inc.QOC 9.4ALNYAlnylam Pharmaceuticals, Inc.QOC 8.3ACRSAclaris Therapeutics, Inc.QOC 7.4ABCLAbCellera Biologics Inc.QOC 7.1ARCTArcturus Therapeutics Holdings QOC 7.0ARVNArvinas, Inc.QOC 6.9AGIOAgios Pharmaceuticals, Inc.QOC 6.8

Read investment analysis: ADMA · ACAD · ALNY · ACRS · ABCL

See all Biotechnology stocks ranked →

Frequently Asked Questions About Anixa Biosciences, Inc.

What is Anixa Biosciences, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Anixa Biosciences, Inc. (ANIX) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.84. The Quality of Company score is 4.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ANIX overvalued or undervalued right now?

At $3.06, 2 of 7 active models suggest ANIX may be undervalued, while 5 indicate potential overvaluation. The assessment depends on which methodology best fits Anixa Biosciences, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.7 mean for ANIX?

Anixa Biosciences, Inc.'s QOC of 4.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ANIX?

CirclFi analyzes ANIX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Is ANIX a value trap in 2026?

Anixa Biosciences, Inc.'s Value Trap score is 6/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on ANIX.

Unlock All 7 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access